Invicro
Academic / Other · 14 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder) | EARLY_Phase 1 | 2025-12-08 |
| Recruiting | First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Ima Progressive Supranuclear Palsy (PSP), Healthy Participants | EARLY_Phase 1 | 2025-11-17 |
| Completed | Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein Parkinson Disease, Multisystem Atrophy, Healthy Volunteer | Phase 1 | 2022-01-31 |
| Completed | Plasma P-tau2017 and Quantitative Amyloid PET Imaging Alzheimer Disease | Phase 1 | 2021-08-27 |
| Completed | Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444 Healthy Volunteer | Phase 1 | 2021-06-24 |
| Completed | Evaluation of [18F]APN-1607 as a PET Biomarker Progressive Supranuclear Palsy, Healthy Volunteers | Phase 1 | 2021-05-25 |
| Completed | Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies | EARLY_Phase 1 | 2020-12-24 |
| Completed | Assessment of the Biodistribution and Safety of [18F]MNI-1054 Healthy Volunteers | Phase 1 | 2018-10-05 |
| Completed | D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562 Healthy Male Volunteers | EARLY_Phase 1 | 2018-09-10 |
| Completed | Assessment of [18F]MNI-1054 as a Marker for LSD1 Healthy Volunteers (HV) | EARLY_Phase 1 | 2018-08-09 |
| Completed | Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss Alzheimer Disease, Parkinson Disease, Healthy Volunteers | Phase 1 | 2018-05-07 |
| Completed | Phase 1 Test-retest Evaluation of [18F]MNI-958 PET Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy | Phase 1 | 2018-03-12 |
| Completed | Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects Healthy Volunteers | Phase 1 | 2017-11-14 |
| Completed | Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein Alzheimer Disease, Healthy Volunteers | EARLY_Phase 1 | 2016-06-01 |